Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Clearside Biomedical Inc    CLSD

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
7.38(c) 7.05(c) 6.94(c) 6.96(c) 7.09(c) Last
82 810 214 272 167 236 100 131 100 217 Volume
+1.10% -4.47% -1.56% +0.29% +1.87% Change
More quotes
Financials ($)
Sales 2017 0,24 M
EBIT 2017 -60,6 M
Net income 2017 -61,0 M
Finance 2017 43,7 M
Yield 2017 -
Sales 2018 0,00 M
EBIT 2018 -69,1 M
Net income 2018 -69,4 M
Debt 2018 3,76 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 576x
EV / Sales2018 55 588x
Capitalization 180 M
More Financials
Company
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which develops drug therapies to treat chronic, blinding diseases of the eye, with a particular emphasis on diseases affecting the choroid and retina.The company was founded by Samirkumar Patel, Vladimir Zarnitsyn, Mark... 
More about the company
Surperformance© ratings of Clearside Biomedical Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on CLEARSIDE BIOMEDICAL INC
11/13 Clearside Biomedical, Inc. to Participate in Stifel 2017 Healthcare Conferenc..
11/13 CLEARSIDE BIOMEDICAL : to Participate in Stifel 2017 Healthcare Conference
11/13 Clearside Biomedical’s Phase 1/2 Open Label Clinical Trial of CLS-TA Wi..
11/09 CLEARSIDE BIOMEDICAL : Management's Discussion and Analysis of Financial Conditi..
11/08 CLEARSIDE BIOMEDICAL, INC. : Results of Operations and Financial Condition, Fina..
11/08 Clearside Biomedical, Inc. Announces Third Quarter 2017 Financial Results and..
11/08 CLEARSIDE BIOMEDICAL INC : Clearside Biomedical, Inc. to Host Earnings Call
11/06 BANK OF NEW YORK MELLON : Has $852,000 Holdings in Clearside Biomedical, Inc. (C..
11/03 CLEARSIDE BIOMEDICAL, INC. (NASDAQ : CLSD) Files An 8-K Entry into a Material De..
11/02 CLEARSIDE BIOMEDICAL, INC. : Entry into a Material Definitive Agreement, Financi..
More news
Sector news : Bio Therapeutic Drugs
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/17 YOUR DAILY PHARMA SCOOP : Gilead CAR-T Potential, Egalet Surges, Aerie Launches ..
11/16 Clearside Biomedical (CLSD) Presents At Stifel 2017 Healthcare Conference - S..
11/08 Clearside Biomedical (CLSD) CEO Daniel White on Q3 2017 Results - Earnings Ca..
11/08 Clearside Biomedical misses by $0.17
10/06 YOUR DAILY PHARMA SCOOP : Gilead, Some History; Biogen's Spinraza, MDCO New Data..
Chart CLEARSIDE BIOMEDICAL INC
Duration : Period :
Clearside Biomedical Inc Technical Analysis Chart | CLSD | US1850631045 | 4-Traders
Technical analysis trends CLEARSIDE BIOMEDICAL INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 20,3 $
Spread / Average Target 186%
EPS Revisions
Managers
NameTitle
Daniel H. White President, Chief Executive Officer & Director
Christy L. Shaffer Chairman
Charles A. Deignan Chief Financial Officer & Head-Investor Relations
Glenn Noronha Chief Scientific Officer
Jennifer M. Kissner Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
CLEARSIDE BIOMEDICAL INC-20.69%180
GILEAD SCIENCES1.16%94 601
REGENERON PHARMACEUTICALS6.67%42 072
VERTEX PHARMACEUTICALS100.10%37 280
GENMAB3.15%11 878
EXELIXIS, INC.76.93%7 805